Stocklytics Platform
Asset logo for symbol CUE
Cue Biopharma
CUE54
$0.52arrow_drop_down7.25%-$0.04
Penny Stock
Asset logo for symbol CUE
CUE54

$0.52

arrow_drop_down7.25%

Performance History

Chart placeholder
Key Stats
Open$0.57
Prev. Close$0.56
EPS-0.97
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$25.48M
PE Ratio-
LOWHIGH
Day Range0.51
0.57
52 Week Range0.51
3.24
Ratios
EPS-0.97

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About Cue Biopharma (CUE)

Cue Biopharma Inc (CUE) is a biotechnology company that is focused on developing a novel class of injectable biologics to selectively engage and modulate targeted T cells within the human body. The company’s proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells), is designed to harness the body’s immune system to enable highly specific and controlled immune responses against disease. Cue Biopharma’s approach is based on the principle of redirecting the immune system to attack and eliminate diseased cells while sparing healthy cells. This targeted therapy has the potential to transform the treatment of a wide range of diseases, including various types of cancer and autoimmune disorders.
Cue Biopharma’s lead product candidate, CUE-101, is being developed for the treatment of HPV+ head and neck squamous cell carcinoma (HNSCC) and is currently in a phase 1 clinical trial. The company’s preclinical pipeline includes additional product candidates targeting solid tumors and infectious diseases. In addition to its internal programs, Cue Biopharma has collaborations with major pharmaceutical companies, including Merck and Bristol-Myers Squibb, to develop novel immunotherapies.
Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Daniel R. Passeri J.D., M.Sc., MSc.
Headquarters
Boston
Employees
51
Exchange
NASDAQ
add Cue Biopharma  to watchlist

Keep an eye on Cue Biopharma

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Cue Biopharma 's (CUE) price per share?

The current price per share for Cue Biopharma (CUE) is $0.52. The stock has seen a price change of -$0.04 recently, indicating a -7.26% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Cue Biopharma (CUE)?

For Cue Biopharma (CUE), the 52-week high is $3.25, which is 520.04% from the current price. The 52-week low is $0.52, the current price is 1.35% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Cue Biopharma (CUE) a growth stock?

Cue Biopharma (CUE) has shown an average price growth of 0.41% over the past three years. It has received a score of 8 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Cue Biopharma as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Cue Biopharma (CUE) stock price performance year to date (YTD)?

As of the latest data, Cue Biopharma (CUE) has a year-to-date price change of -81.15%. Over the past month, the stock has experienced a price change of -35.71%. Over the last three months, the change has been -64.35%. Over the past six months, the figure is -72.42%. Looking at a longer horizon, the five-year price change stands at -94.05%.
help

Is Cue Biopharma (CUE) a profitable company?

Cue Biopharma (CUE) has a net income of -$50.73M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 37.41% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -390.63% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $5.49M, although specific revenue growth data is currently not available. The gross profit is $2.05M. Operating income is noted at -$51.99M. Furthermore, the EBITDA is -$47.71M.
help

What is the market capitalization of Cue Biopharma (CUE)?

Cue Biopharma (CUE) has a market capitalization of $25.49M. The average daily trading volume is 153.68K, indicating the stock's liquidity and investor engagement.

News

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level

Stocklytics Platform

© 2024 Stocklytics.com All rights reserved.

Stocklytics.com is not a financial advisor, and all data and information provided on this website are for informational purposes only. The content on Stocklytics.com is not intended to be a substitute for professional financial advice. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions. Stocklytics.com makes no representations or warranties regarding the accuracy, completeness, or suitability of any information provided and is not liable for any errors or omissions, or for any losses incurred as a result of reliance on the information provided on this website.

Stocklytics Discord public channelStocklytics X Social Media